This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
by Zacks Equity Research
Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare are part of the Zacks top Analyst Blog.
Cigna (CI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat
by Kaibalya Pravo Dey
Growing patient volumes, advancements in technology, admissions, premium rate hikes and other factors are likely to have benefited healthcare players during Q1. Companies like CI, HCA, AVTR and THC can outperform.
Cigna (CI) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Cigna (CI) stood at $352.65, denoting a -0.15% change from the preceding trading day.
Here's Why Cigna (CI) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why the Market Dipped But Cigna (CI) Gained Today
by Zacks Equity Research
Cigna (CI) closed at $348.78 in the latest trading session, marking a +0.78% move from the prior day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
UnitedHealth Group (UNH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 4.22% and 0.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Stock Moves -0.92%: What You Should Know
by Zacks Equity Research
Cigna (CI) reachead $349.84 at the closing of the latest trading day, reflecting a -0.92% change compared to its last close.
Acadia Healthcare (ACHC) Opens Facility to Address Mental Health
by Zacks Equity Research
Acadia Healthcare (ACHC) inaugurates an acute care hospital in Mesa, AZ, to cater to patients struggling with addiction and mental health issues in the area.
Here's Why Cigna (CI) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Brookdale Senior (BKD) Sees Y/Y Increase in Q1 Occupancy Levels
by Zacks Equity Research
Brookdale Senior (BKD) witnesses 29 straight months of year-over-year increases in weighted average occupancy level.
CI vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
Compelling Reasons to Hold Acadia Healthcare (ACHC) Stock Now
by Zacks Equity Research
Growing commercial, Medicare and Medicaid revenues will likely boost Acadia Healthcare's (ACHC) top line.
Cigna (CI) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
Cigna (CI) closed the most recent trading day at $360.37, moving -0.19% from the previous trading session.
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.
5 Low Price-to-Sales Stocks Poised to Race up the Charts
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like KBH, AMG, CI, BBSI and JAKK hold promise.
Humana's (HUM) Medicaid Business Teams Up With CPESN USA in Ohio
by Zacks Equity Research
Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.
Select Medical (SEM) Expands in Florida With UF Health JV
by Zacks Equity Research
Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.
UnitedHealth's (UNH) Optum to Buy Steward's Physician Group
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Steward Health's physician group is expected to close in the second quarter of 2024.
Top Research Reports for Walmart, Linde & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Linde plc (LIN) and International Business Machines Corporation (IBM).
Acadia (ACHC) Starts Construction of Malden's JV Facility
by Zacks Equity Research
Acadia Healthcare (ACHC) initiates the construction work of the 144-bed Massachusetts-based joint venture hospital in a bid to address the need for efficient behavioral health services in the region.
Here's How Much a $1000 Investment in Cigna Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.